AI Image
GLP-1s often contain untested additive combinations, study finds
Medical Xpress • • health
Key Points:
- The use of compounded GLP-1 receptor agonist medications for weight loss has surged, now accounting for 86% of compounded weight-loss prescriptions in Nebraska by 2025, according to a new study published in JAMA.
- These compounded products often include additives like vitamin B12 analogs and levocarnitine, which lack evidence for safety or efficacy when combined with GLP-1s and are not regulated by the FDA.
- Because compounded GLP-1s are mostly paid for in cash and obtained outside traditional pharmacy channels, they are largely invisible in insurance claims data, making it difficult to track their use and safety.
- Researchers highlight the unknown risks associated with these compounded medications, emphasizing that their composition and quality are often unverifiable compared to FDA-approved GLP-1 drugs.
- The study calls for improved safety monitoring, better tracking of compounded medications, and urges healthcare providers to actively inquire about patients’ use of compounded GLP-1 products, especially those acquired online.
